RxDoctor Payments Data

Vibha Sabharwal, MD

Urology · Bolingbrook, ILNPI 1235171943

Payments from drug & device makers

$13,043in general payments, 2019–2025

Across 477 payments — averaging $27.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$4K
  • Astellas Pharma US Inc$1K
  • Sumitomo Pharma America, Inc.$911
  • Urovant Sciences Inc$832
  • Boston Scientific$762
  • Coloplast$616
  • plus $5K from 35 others

What the payments were for

  • Consulting fees$5004%
  • Speaking & faculty fees$5004%
  • Travel & lodging$1,49911%
  • Food & beverage$9,96076%
  • Education$5844%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,043 in reported general payments places this provider in the 80th percentile of 550 urology providers in Illinois.

See all urology providers in Illinois

Medicare billing

Part B allowed, 2024
$184,983
Medicare patients
391
Services billed
3,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide11$160,111
GemtesaVibegron118$109,851
MyrbetriqMirabegron93$81,980
OrgovyxRelugolix31$80,690
Solifenacin Succinate281$10,327
Finasteride341$5,054
Tamsulosin Hcl452$4,639
Potassium Citrate ErPotassium Citrate90$3,997
Bethanechol Chloride63$3,205
Estradiol37$2,465
Trimethoprim39$2,247
Cefdinir153$2,084
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst116$1,620
Alfuzosin Hcl ErAlfuzosin Hcl81$1,327
Silodosin17$1,074

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,356$242,091104 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$911$190,541149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 550 urology providers in Illinois.

Other urology in Bolingbrook

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →